North America Left Atrial Appendage Closure Devices Market Size, Share and Trends (2025 to 2032)

The North America Left Atrial Appendage Closure Devices Market size was valued at USD 757.46 Mn in 2024, and the total North America Left Atrial Appendage Closure Devices revenue is expected to grow at a CAGR of 20.5% from 2025 to 2032, reaching nearly USD 3367.10 Mn.
North America Left Atrial Appendage Closure Devices Market Overview
Left Atrial Appendage Closure devices are implantable or surgical tools designed to seal the left atrial appendage (LAA) in atrial fibrillation patients, preventing blood clots and reducing stroke risk. They include catheter-deployed plugs or surgical clips.

The North American Left Atrial Appendage Closure devices market on rising AFib prevalence and stroke risks, though high costs and complications pose challenges. Dominated by endocardial devices and percutaneous procedures, the market benefits from technological advancements and expanding FDA approvals. The U.S. leads due to robust reimbursement and advanced healthcare infrastructure, while Canada lags. Boston Scientific (Watchman) and Abbott (Amulet) dominate the competitive landscape, leveraging FDA approvals and clinical data, leaving minimal room for new entrants in this high-growth, innovation-driven sector.
North America Left Atrial Appendage Closure Devices Market Recent Development



Date
Company
Recent Development


November-16-2024
Boston Scientific
Presented positive three-year results from the OPTION trial, demonstrating the WATCHMAN FLX device's superiority over oral anticoagulants in reducing bleeding risk post-cardiac ablation, highlighting a significant advancement for Left Atrial Appendage Closure Devices manufacturers.


September-6-2023
Boston Scientific
Received FDA approval for the WATCHMAN FLX™ Pro Left Atrial Appendage Closure device, featuring a polymer coating and enhanced visualization markers to improve procedural performance and safety, marking a key milestone in the Left Atrial Appendage Closure Devices market.


November-30-2023
Johnson & Johnson
Acquired Laminar, a company developing a novel Left Atrial Appendage Closure technology, for $400 million, marking J&J's entry into the Left Atrial Appendage Closure Devices market




To know about the Research Methodology :- Request Free Sample Report
North America Left Atrial Appendage Closure Devices Market Dynamics
Technological Advancements Boost the North America Left Atrial Appendage Closure Devices Market Growth

Enhancing safety and efficacy. Next-gen devices like Watchman FLX offer improved scalability and easier deployment, reducing complications. Innovations such as real-time imaging integration and miniaturized delivery systems further optimize procedures. These improvements boost physician confidence and patient outcomes, driving adoption. Additionally, ongoing clinical trials validating long-term benefits strengthen reimbursement support, ensuring sustained market growth across North America’s evolving cardiac care landscape.Limited Physician Training and Procedural Expertise Restrain the North America Left Atrial Appendage Closure Devices Market

The complex nature of percutaneous Left Atrial Appendage Closure Devices demands specialized interventional cardiologists and electrophysiologists, creating a shortage of qualified operators. This skills gap restricts widespread adoption, particularly in community hospitals, and may lead to inconsistent procedural outcomes. Additionally, the steep learning curve for new devices could temporarily slow market expansion despite growing clinical demand.

Restraints and Their Impact on Market Growth



Restraint/Challenge
Impact on Market Growth
Supporting Data/Statistics


High Device & Procedure Cost
Limits adoption among cost-sensitive patients & smaller healthcare facilities.
Average left Atrial Appendage Closure procedure costs $20,000–$30,000 (vs. long-term anticoagulants at $2,000–$5,000/year).


Device-Related Thrombosis
Post-implant blood clot risks may deter physicians & patients despite anticoagulant use.
Occurs in 3–7% of Left Atrial Appendage Closure cases (Journal of the American College of Cardiology).


Pericardial Effusion
Fluid accumulation around the heart may require emergency intervention.
Reported in 2–4% of procedures (FDA MAUDE database).


Procedural Complexity
Requires skilled electrophysiologists; learning curve slows adoption.
Only ~40% of U.S. hospitals perform LAAC routinely (2023 survey).



Technological Advancements and Expanding Indications to Create North America Left Atrial Appendage Closure Devices Market Opportunities

North America's Left Atrial Appendage Closure devices market is seeing significant growth due to technological progress, including increased safety, small profiles, and easy deployment in the next generation of equipment. Real-time imaging reduces innovation complications, such as integration and better sealing mechanisms. Additionally, expanding FDA approval for the wider patient population, which includes long-term anticoagulants, creates new opportunities. Demand to move forward by increasing physician training programs and minimally invasive processes. Companies investing in R&D and AI-assisted implantation techniques are ready to capitalize on this extended market, which ensures better results and widespread access.

North America Left Atrial Appendage Closure Devices Market Opportunities and Their Impact on Market Growth



Opportunity
Impact on Market Growth


Next-Gen LAAC Devices
Improved safety, smaller profiles, and easier deployment increase adoption.


Real-Time Imaging Integration
Reduces procedural complications (e.g., leaks, misplacement).


Expanding FDA Approvals
Broader patient eligibility (e.g., moderate-risk AFib patients).


Growing Physician Training Programs
Increased adoption as more cardiologists gain expertise.


AI & Robotics in LAAC Procedures
Enhances precision, reduces human error, and shortens procedure time.



Stringent Regulatory Approvals and Competition to Create North America Left Atrial Appendage Closure Devices Market Challenge

The North American Left Atrial Appendage Closure device market faces obstacles due to strict FDA and Health Canada regulations, requiring extensive clinical testing and long approval deadlines. High growth costs and strong long-term security data delay require market entry. Additionally, intensive competition between established players and entrants puts pressure on pricing and margins. Companies should also navigate reimbursement complexities and display better efficacy for gaining adoption. These challenges create obstacles for small firms while pushing big players to maintain heavy investment in compliance and innovation to maintain market share.
North America Left Atrial Appendage Closure Devices Market Segment Analysis
Based on Product Type, the North American Left Atrial Appendage Closure Devices Market is segmented into Endocardial (Implantable) Devices and Epicardial (Surgical) Devices. The endocardial (Implantable) Devices Segment has dominated the North American left Atrial Appendage Closure Devices Market in 2024 and is expected to hold the largest market share over the forecast period. Due to their minimally invasive nature, broader clinical adoption, and strong FDA approvals (e.g., Watchman FLX, Amulet). Endocardial devices are preferred because they can be implanted via catheter-based procedures, reducing surgical risks, hospital stays, and recovery time compared to epicardial devices, which require open-heart or thoracoscopic surgery. Additionally, endocardial devices have extensive clinical validation for stroke prevention in atrial fibrillation patients, favorable reimbursement policies, and are more widely available, making them the first-line choice for most physicians and patients in the U.S. and Canada.

Based on Procedure Type, the North America Left Atrial Appendage Closure Devices Market is segmented into Percutaneous (Catheter-based) Closure and Surgical Left Atrial Appendage Closure. The percutaneous Closure Segment has dominated the North American left Atrial Appendage Closure Devices Market in 2024 and is expected to hold the largest market share over the forecast period. Due to its minimally invasive approach, it reduces surgical risks, hospital stays, and recovery time compared to surgical methods. Key drivers include strong clinical evidence (e.g., Watchman trials), FDA approvals, and favorable reimbursement policies. Additionally, the growing preference for outpatient procedures and advancements in catheter-based technologies enhance adoption. With rising atrial fibrillation cases and demand for safer alternatives to blood thinners, percutaneous closure remains the preferred choice, securing its leading market position.

• Cardiologist preference: ~80% of electrophysiologists favor transcatheter over surgical approaches.

• Outpatient adoption: ~40% of percutaneous Left Atrial Appendage Closure Devices procedures are now performed in ASCs/outpatient settings.

• Device innovation: Next-gen devices (e.g., Watchman FLX, Amulet) reduce complications (major adverse events <3%).

Based on End-User, the North American Left Atrial Appendage Closure Devices Market is segmented into Hospitals, Cardiac Centers & Specialty Clinics, and Ambulatory Surgical Centers (ASCs). The Hospitals Segment has dominated the North American left Atrial Appendage Closure Devices Market in 2024 and is expected to hold the largest market share over the forecast period. Dominance is due to their advanced cardiac catheterization labs, ability to manage complex cases (e.g., concomitant surgeries), and reimbursement support (70% of procedures covered under Medicare). Cardiac centers and specialty clinics accounted for 25%, leveraging high-volume AFib care and cost efficiencies, while ASCs, though smaller (10%), are the fastest-growing segment (18% CAGR) due to the outpatient shift and CMS policies incentivizing lower-cost settings.

Critical Trends:

• Hospitals remain the hub for training and complex cases, but ASCs are gaining traction for routine Left Atrial

Appendage Closure Devices (e.g., Watchman FLX procedures).

• Reimbursement disparities: Hospitals average $15,000–$20,000 per LAAC, while ASCs cost $10,000–$12,000.

• Referral networks: 60% of ASC Left Atrial Appendage Closure Devices cases originate from hospital-affiliated cardiology groups.
North America Left Atrial Appendage Closure Devices Market Country Analysis
The North America Left Atrial Appendage Closure Devices Market is dominated by the United States, which exceeds the regional market share, while Canada represents the remaining part. This lopsided distribution is primarily driven by the U.S.'s higher prevalence of atrial fibrillation, stronger reimbursement policies, greater adoption of innovative medical technologies, and a more extensive network of specialized cardiac centers. The US market benefits from the FDA approval of devices such as Watchman and Amulet, strong physician training programs, and high healthcare expenses from the FDA.

Key Metrics and Trends in the North America Left Atrial Appendage Closure Devices Market: Focus on the United States



Key Aspect
Metric
2024 Data
Significance


Patient Pool
AFib Cases (LAAC-eligible)
6-12M (2.5-4M eligible)
Largest addressable market globally


Procedures
Annual LAAC Implants
~60,000 (+15% YoY)
Rapid adoption curve


Market Leaders
Boston Scientific (Share)
85% ($1.1B revenue)
Watchman FLX dominance


Cost/Setting
ASC vs Hospital Cost
$10K vs $18K
40% moving to ASCs by 2030



North America Left Atrial Appendage Closure Devices Market Technological Leadership
• Watchman FLX (Boston Scientific) dominates with 96% implant success rates.
• Amplatzer Amulet (Abbott), approved in 2023, expanded options.
North America Left Atrial Appendage Closure Devices Market Competitive Landscape
The global Left Atrial Appendage Closure Device market is dominated by three U.S. giants: Boston Scientific leads with FDA-first approvals, robust clinical data, and global training programs. Abbott Laboratories follows as the strongest competitor, leveraging its dual-seal design and early CE mark in Europe. AtriCure controls the surgical niche. While Boston Scientific and Abbott compete head-to-head in percutaneous closure, AtriCure dominates concurrent surgical procedures. Emerging Chinese (Lifetech’s Lambre) and European (Cardia’s Ultraseal) players challenge regionally but lack global scale. The trio’s IP portfolios, reimbursement strategies, and physician training cement their lead, leaving minimal space for new entrants.
North America Left Atrial Appendage Closure Devices Market Scope: Inquire before buying



North America Left Atrial Appendage Closure Devices Market


Report Coverage
Details


Base Year:
2024
Forecast Period:
2025-2032


Historical Data:
2019 to 2024
Market Size in 2024:
USD 757.46 Mn.


Forecast Period 2025 to 2032 CAGR:
20.5%
Market Size in 2032:
USD 3367.10 Mn.


 Segments Covered:
by Product Type
Endocardial (Implantable) Devices
Epicardial (Surgical) Devices


by Procedure Type
Percutaneous (Catheter-based) Closure
Surgical LAA Closure


by End-Users
Hospitals
Cardiac Centers & Specialty Clinics
Ambulatory Surgical Centers (ASCs)



North America Left Atrial Appendage Closure Devices Market by Country
North America (United States, Canada, and Mexico)
North America Left Atrial Appendage Closure Devices Market Key Players
1. Boston Scientific Corporation, USA
2. Abbott Laboratories, USA
3. AtriCure, Inc., USA
4. Johnson & Johnson, USA
5. Medtronic plc, USA
6. Cardia, Inc., USA
7. SentreHEART, Inc., USA
8. Coherex Medical, Inc., USA
9. Conformal Medical, Inc., USA
10. EpiEP, Inc., USA
11. LifeTech Scientific, USA
12. Occlutech, Inc., USA
Frequently Asked Questions
Q1: Which product type leads the North American left Atrial Appendage Closure Devices market and why?
Ans: Endocardial devices (like Watchman) dominate (~85% share) due to minimally invasive implantation and strong FDA/CMS support.

Q2: Why does the U.S. dominate Canada in Left Atrial Appendage Closure adoption?
Ans: The U.S. has higher AFib rates, better reimbursement (CMS), and earlier FDA approvals for devices.

Q3: How does reimbursement affect the Left Atrial Appendage Closure Device market?
Ans: CMS coverage in the U.S. boosts adoption, while Canada’s stricter cost reviews of slow growth.

Q4: What limits new Left Atrial Appendage Closure Device competitors?
Ans: High costs, strict FDA rules, and competition from leaders (Boston Scientific, Abbott) create barriers.

Q5: Why do hospitals perform most Left Atrial Appendage Closure Device procedures?
Ans: Hospitals have specialized teams and advanced cardiac catheterization labs, and can handle complications better than ASCs.